Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 1 • 2017 Pediatric Rheumatology Symposium
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Improvement on Quality Measures for Children with Juvenile Idiopathic Arthritis
C. April Bingham¹, Jesse Pratt², Cagri Yildirim-Toruner³, Ronald Laxer⁴, Beth Gottlieb⁵, Jennifer Weiss⁶, Tzielan Lee⁷, Sheetal S. Vora⁸, Jon Burnham⁹, Julia Harris¹⁰, Judyann C. Olson¹¹, Murray Passo¹², Michelle Batthish¹³, Michael Shishov¹⁴, Kerry Ferraro¹⁵, Deborah M. Levy¹⁶, Christine O'Brien¹⁷, Kristi Whitney-Mahoney¹⁷, Nancy Griffin¹⁸, Anne Paul¹⁹ and Esi Morgan²⁰, ¹Penn State Health Children's Hospital, Hershey, PA, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁴Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ⁶Hackensack University Medical Center, Hackensack, NJ, ⁷Pediatric Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁸Pediatric Rheumatology, Levine Children's Hospital, Charlotte, NC, ⁹Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰Children's Mercy Kansas City, Kansas City, MO, ¹¹Ped/MACC Fund Research Ctr, Medical College of Wisconsin, Milwaukee, WI, ¹²Division of Rheumatology PTD, Medical University of South Carolina, Charleston, SC, ¹³Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, ¹⁴Pediatric Rheumatology, Phoenix Children's Hospital, Phoenix, AZ, ¹⁵Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ¹⁶Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁷The Hospital for Sick Children, Toronto, ON, Canada, ¹⁸James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁹Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁰Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a growing multi-center network organized on a learning health system model designed to improve outcomes…
Abstract Number: 49 • 2017 Pediatric Rheumatology Symposium
Perceptions of Methotrexate Intolerance in School-aged Children With Juvenile Idiopathic Arthritis
Charlene Hopper¹, Sarah Khan², Jacqueline Mancini² and Janet Rennick^3,4, ¹Rheumatology, Montreal Children's Hospital McGill University Health Centre, Montreal, QC, Canada, ²Ingram School of Nursing, McGill University, Montreal, QC, Canada, ³Nursing, Montreal Children's Hospital McGill University Health Centre, Montreal, QC, Canada, ⁴Ingram School of Nursing and Department of Pediatrics, McGill University, Montreal, QC, Canada
Background/Purpose: Methotrexate (MTX) remains an effective and commonly used disease modifying anti-rheumatic drug (DMARD) for the treatment of Juvenile Idiopathic Arthritis (JIA). Approximately half of the children taking MTX will…
Abstract Number: 67 • 2017 Pediatric Rheumatology Symposium
Relapse and Remission in Children with Chronic Non-Infectious Uveitis Treated with Methotrexate and Tumor Necrosis Factor-α Inhibitors
Courtney McCracken¹, Curtis Travers¹, Kirsten Jenkins², Carolyn Drews-Botsch³, Steven Yeh⁴, Sampath Prahalad^1,5 and Sheila Angeles-Han^6,7, ¹Pediatrics, Emory University School of Medicine, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Epidemiology, Emory University School of Public Health, Atlanta, GA, ⁴Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁵Pediatrics, Emory Children's Center, Atlanta, GA, ⁶Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Pediatrics, University of Cincinnati, Cincinnati, OH
Background/Purpose: Methotrexate (MTX) and tumor necrosis factor-α inhibitors (TNFi) are common treatments for children with chronic non-infectious uveitis (NIU). Optimal duration of treatment prior to…
Abstract Number: 11 • 2017 Pediatric Rheumatology Symposium
Safety of Adalimumab ± Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA): STRIVE Registry
Hermine Brunner¹, Nicolino Ruperto², Kabita Nanda³, Mary Toth⁴, Ivan Foeldvari⁵, John F. Bohnsack⁶, Diana Milojevic⁷, C. Egla Rabinovich⁸, Daniel Kingsbury⁹, Katherine Marzan¹⁰, Pierre Quartier¹¹, Kirsten Minden¹², Elizabeth Chalom¹³, Gerd Horneff¹⁴, Rolf M. Kuester¹⁵, Jason A Dare¹⁶, Mareike Bereswill¹⁷, Jasmina Kalabic¹⁷, Hartmut Kupper¹⁸, Daniel J. Lovell¹⁹ and Alberto Martini², ¹Rheumatology, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²PRINTO-IRCCS Gaslini, Genova, Italy, ³Seattle Childrens Hospital, Bayside, NY, ⁴Rheumatology, Akron Children's Hospital, Akron, OH, ⁵Kinder- und Jugenrheumatologie, Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, ⁶Division of Allergy, Immunology and Pediatric Rheumatology, University of Utah, Salt Lake City, UT, ⁷Tufts Medical Center, Boston, MA, ⁸Duke University Medical Center, Durham, NJ, ⁹Pediatric Rheumatology, Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹⁰Children's Hospital Los Angeles, Los Angeles, CA, ¹¹Hopital Necker-Enfants Malades, Paris, France, ¹²Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ¹³PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁴Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ¹⁵Orthopädiezentrum Altona, Hamburg, Germany, ¹⁶Arkansas Children’s Hospital, Little Rock, AR, ¹⁷AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ¹⁸Clinical Oncology/Immunology, AbbVie Deutschland GmbH & Co. KG, Ludnigshafen, Germany, ¹⁹Rheumatology MLC 4010, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: JIA is the most common chronic inflammatory rheumatic disease of childhood. Due to their known safety and efficacy, TNF inhibitors are used for long-term…
Abstract Number: 48 • 2017 Pediatric Rheumatology Symposium
Methotrexate use and route of administration in JIA: Results from the Childhood Arthritis & Rheumatology Research Alliance Registry
Sarah Ringold¹, Fenglong Xie², Yukiko Kimura³, Laura E. Schanberg⁴, Timothy Beukelman⁵ and and the CARRA Registry Investigators, ¹Seattle Children's Hospital, Seattle, WA, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Hackensack University Medical Center, Hackensack, NJ, ⁴Pediatrics, Duke Medical Center, Durham, NC, ⁵Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry began enrolling children with juvenile idiopathic arthritis (JIA) in July 2015. The large number of…
Abstract Number: 42 • 2017 Pediatric Rheumatology Symposium
Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than Two Years of Age With Systemic Juvenile Idiopathic Arthritis
Navita L. Mallalieu¹, Joy Hsu¹, Karen Wang¹, Sunethra Wimalasundera², Chris Wells², Inmaculada Calvo Penades³, Rubén J. Cuttica⁴, Hans-Iko Huppertz⁵, Rik Joos⁶, Yukiko Kimura⁷, Diana Milojevic⁸, Margalit Rosenkranz⁹, Kenneth Schikler¹⁰, Tamas Constantin¹¹ and Carine Wouters¹², ¹Roche Innovation Center, New York, NY, ²Roche Products Ltd., Welwyn Garden City, United Kingdom, ³Hospital Universitario y Polytécnico La Fe, Valencia, Spain, ⁴Hospital General de Niños Pedro de Elizalde, Buenes Aires, Argentina, ⁵Professor Hess Children's Hospital, Bremen, Germany, ⁶ZNA Jan Palfijn Antwerpen, Antwerp, Belgium, ⁷Hackensack University Medical Center, Hackensack, NJ, ⁸Tufts Medical Center, Boston, MA, ⁹Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ¹⁰University of Louisville Hospital, Louisville, KY, ¹¹Semmelweis University, Budapest, Hungary, ¹²University Hospital Gasthuisberg, Leuven, Belgium
Background/Purpose: Tocilizumab (TCZ) is approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) based on clinical trials in patients ≥2 years of age. This…
Abstract Number: 141 • 2017 Pediatric Rheumatology Symposium
Expression of Siglec-10 on Synovial Fluid CD14dim Monocytes Was Decreased in Juvenile Idiopathic Arthritis Patients
Qianzi Zhao¹, Yang Liu², Pan Zheng² and Lawrence Jung³, ¹Rheumatology, Children's National Medical Center, Washington, DC, ²Cancer and Immunology Research Center, Children's National Medical Center, Washington, DC, ³Pediatric Rheumatology, Children's National Medical Center, Washington, DC
Background/Purpose: Monocytes plays a role in juvenile idiopathic arthritis (JIA). CD14dim monocytes have modulatory effects in innate and adaptive immune responses. Siglec-10, which is highly…
Abstract Number: 41 • 2017 Pediatric Rheumatology Symposium
Identification of Optimal Subcutaneous Doses of Tocilizumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis
Hermine Brunner¹, Nicola Ruperto², Alberto Martini², Athimalaipet Ramanan³, Rubén Cuttica⁴, Jennifer E. Weiss⁵, Michael Henrickson⁶, Heinrike Schmeling⁷, Jordi Anton⁸, Kirsten Minden⁹, Joy Hsu¹⁰, Kamal Bharucha¹¹, Sunethra Wimalasundera¹², Alysha K. Kadva¹³, Ruchi Upmanyu¹², Navita L. Mallalieu¹⁰, Daniel Lovell⁶ and Fabrizio De Benedetti¹⁴, ¹Rheumatology, PRCSG, Cincinnati, OH, ²PRINTO Coordinating Centre, Genoa, Italy, ³Bristol Royal Hospital for Children, Bristol, United Kingdom, ⁴Hospital Gral de Niños Pedro Elizalde, Buenos Aires, Argentina, ⁵Hackensack University Medical Center, Hackensack, NJ, ⁶PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁷University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ⁸Hospital Sant Joan de Deu, Barcelona, Spain, ⁹Charité – University of Medicine Berlin, Berlin, Germany, ¹⁰Roche Innovation Center, New York, NY, ¹¹Genentech, South San Francisco, CA, ¹²Roche Products Ltd., Welwyn Garden City, United Kingdom, ¹³Genentech, San Francisco, CA, ¹⁴IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
Background/Purpose: The efficacy and safety of intravenous (IV) tocilizumab (TCZ), an interleukin-6 receptor-alpha inhibitor, have been demonstrated in patients (pts) with polyarticular-course juvenile idiopathic…
Abstract Number: 12 • 2017 Pediatric Rheumatology Symposium
Use of Ultrasound to Determine Remission Status in Children with Juvenile Idiopathic Arthritis
Ottar Kristinsson¹, Lisabeth Scalzi², Michael Bruno², Cristy French², Vernon Chinchilli² and Brandt Groh², ¹Pediatrics, Penn State Hershey Medical Center, Hershey, PA, ²Penn State Hershey Medical Center, Hershey, PA
Background/Purpose: The ultimate goal for clinicians caring for children with Juvenile idiopathic arthritis (JIA) is to attain disease remission off medications. Correct identification of remission…
Abstract Number: 947 • 2016 ACR/ARHP Annual Meeting
A Multi-Center, Open-Label Study to Assess the Pharmacokinetics, Efficacy and Safety of Certolizumab Pegol in Children and Adolescents with Moderately to Severely Active Polyarticular-Course Juvenile Idiopathic Arthritis: Week 24 Results
Hermine I. Brunner¹, Nicolino Ruperto², Vladimir Keltsev³, Ekaterina Alexeeva⁴, Carlos Abud-Mendoza⁵, Heinrike Schmeling⁶, María del Rocío Maldonado-Velázquez⁷, Nadina Rubio-Pérez⁸, Marina Stanislav⁹, Vyacheslav Chasnyk¹⁰, Diane Brown¹¹, Michael Henrickson¹, Daniel Kingsbury¹², C. Egla Rabinovich¹³, Andrew Zeft¹⁴, Earl Silverman¹⁵, Maggie Wang¹⁶, Philippa Charlton¹⁶, Rocio Lledo-Garcia¹⁷, Laura Shaughnessy¹⁶, Daniel J. Lovell¹ and Alberto Martini², ¹PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²PRINTO, Istituto Gaslini, Genoa, Italy, ³Togliatti City Clinical Hospital №5, Togliatti, Russian Federation, ⁴Children's Health of RAMS and IM Sechenov First Moscow State Medical University, Moscow, Russian Federation, ⁵Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁶Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, ⁷Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico, ⁸Universidad Autónoma de Nuevo León, Nuevo León, Mexico, ⁹Research Rheumatology Institute V.A. Nassonova, Moscow, Russia, ¹⁰St Petersburg State Pediatric Medical Academy, St Petersburg, Russian Federation, ¹¹Division of Rheumatology, Children's Hospital of Los Angeles and University of Southern California, Los Angeles, CA, ¹²Pediatric Rheumatology, Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹³Duke University Medical Center, Durham, NC, ¹⁴Cleveland Clinic, Pediatric Rheumatology, Cleveland, OH, ¹⁵Hospital for Sick Children, Toronto, ON, Canada, ¹⁶UCB Pharma, Raleigh, NC, ¹⁷UCB Pharma, Slough, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) often requires biologic medication to control polyarticular disease courses. This study assesses the pharmacokinetics (PK), efficacy and safety of certolizumab…
Abstract Number: 112 • 2016 ACR/ARHP Annual Meeting
Leveraging a Learning Network to Implement and Standardize Self-Management Support into Care Delivery: Experience of Pediatric Rheumatology Care and Outcomes Improvement Network
Janalee Taylor¹, Avani Modi², Kristin Loiselle², Julie Gomez³, Karla B. Jones⁴, Sheetal S. Vora⁵, Julia Harris⁶, Beth Gottlieb⁷, Lisa Robbins⁸, Tzielan Lee⁹, Kristi Whitney-Mahoney¹⁰, Murray Passo¹¹, Melanie Kohlheim¹², Laura Curtis¹², Anjie Vago¹³, Kerry Ferraro¹², Kate Trevey¹², Jennifer Gil¹², Laura Bouslaugh¹², Angela Young¹², Nancy Griffin¹⁴, Anne Paul¹⁵, Carole M. Lannon¹⁴ and Esi Morgan¹⁶, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Center for Treatment Adherence and Self-Management, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Rheumatology, Nationwide Children's, Columbus, OH, ⁵Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁶Children's Mercy Kansas City, Kansas City, MO, ⁷Pediatrics, Cohen Children's Medical Center, Lake Success, NY, ⁸Penn State Hershey Children's Hospital, Hershey, PA, ⁹Pediatric Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ¹⁰The Hospital for Sick Children, Toronto, ON, Canada, ¹¹Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ¹²Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ¹³Pediatric Rheumatology Care and Outcomes Improvement Network, cincinnati, OH, ¹⁴James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁵Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁶Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Disease outcomes can depend, to a large extent, on one’s ability to manage their condition effectively. For children with JIA this means managing oral,…
Abstract Number: 948 • 2016 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients with Polyarticular-Course Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Efficacy and Safety
DJ Lovell¹, N Ruperto², N Tzaribachev³, G Vega-Cornejo⁴, I Louw⁵, A Berman^6,7, I Calvo⁸, R Cuttica⁹, G Horneff¹⁰, F Avila-Zapata¹¹, J Anton¹², R Cimaz¹³, E Solau-Gervais¹⁴, R Joos¹⁵, G Espada¹⁶, X Li¹⁷, M Nys¹⁸, R Wong¹⁷, S Banerjee¹⁷, Hermine I. Brunner¹⁹, A Martini²⁰ and For Pediatric Rheumatology International Trials Organization (PRINTO)/Pediatric Rheumatology Collaborative Study Group (PRCSG), ¹Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Istituto G. Gaslini Pediatria II Reumatologia, Genoa, Italy, ³Pediatric Rheumatology, Bad Bramstedt, Germany, ⁴Clinica de Rheumatología y Enfermedades Autoinmunes (CREA), Hospital México Americano, Guadalajara Jalisco, Mexico, ⁵Panorama Medical Centre, Cape Town, South Africa, ⁶Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁷Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁸Hospital Univ. La Fe, Valencia, Spain, ⁹Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ¹⁰Centre Paediatric Rheumatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹¹Star Medica Hospital, Merida, Mexico, ¹²Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ¹³Pediatrics, Ospedale Pediatrico Anna Meyer, Florence, Italy, ¹⁴Hôpital de la Miletrie, Poitiers, France, ¹⁵University Hospital Gent, Gent, Belgium, ¹⁶Cramer 1853 4°C, Hospital de Ninos Dr Ricardo Gutierrez, Buenos Aires, Argentina, ¹⁷Bristol-Myers Squibb, Princeton, NJ, ¹⁸Bristol-Myers Squibb, Braine-l’Alleud, Belgium, ¹⁹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁰Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genoa, Italy
Background/Purpose: IV abatacept (ABA) 10 mg/kg every 4 weeks was well tolerated and effective in reducing the signs and symptoms of polyarticular-course juvenile idiopathic arthritis…
Abstract Number: 335 • 2016 ACR/ARHP Annual Meeting
High Risk of Osteoporosis and Long Term Joint Damage in Adults with a History of Juvenile Idiopathic Arthritis
Hiranda Dodanwala¹, Danielle Feger¹, Nicholas Longson², Nancy J. Olsen³, Barbara E. Ostrov^4,5 and Rayford R. June⁶, ¹Medicine - Division of Rheumatology, Penn State Milton S. Hershey Medical Center, Hershey, PA, ²Johns Hopkins University, Baltimore, MD, ³Divsion of Rheumatology, Department of Medicine, Penn State MS Hershey Medical Center, Hershey, PA, ⁴Pediatrics, Penn State Hershey Medical Center, Hershey, PA, ⁵Pediatrics, Penn State Hershey Children's Hospital, Hershey, PA, ⁶Rheumatology, Penn State Hershey Medical Center, Hershey, PA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a heterogeneous group of chronic inflammatory arthritides. JIA is the most common cause of musculoskeletal disability in children, and…
Abstract Number: 949 • 2016 ACR/ARHP Annual Meeting
Comparison of Treatment Response, Remission Rate and Drug Adherence in Polyarticular Juvenile Idiopathic Arthritis Patients Treated with Etanercept, Adalimumab or Tocilizumab
Gerd Horneff^1,2, Ariane Klein³, Kirsten Minden^4,5, Hans-Iko Huppertz⁶, Frank Weller-Heinemann⁷, Jasmin B. Kuemmerle-Deschner⁸, Johannes Peter Haas⁹ and Toni Hospach¹⁰, ¹Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ²Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, ³Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁴Epidemiology, Charite, DRFZ, Berlin, Germany, ⁵Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ⁶Klinikum Bremen-Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany, ⁷Prof.-Hess-Kinderklinik, Bremen,, Berlin, Germany, ⁸Universitätsklinikum Tübingen, Klinik fuer Kinder- und Jugendmedizin, Tübingen, Germany, ⁹German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ¹⁰Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany
Background/Purpose: Treatment response, remission rates and compliance in polyarticular JIA patients treated with adalimumab(ADA), etanercept(ETA), or tocilizumab(TCZ) were analyzed in clinical practice. Methods: Data from the German BIKER…
Abstract Number: 376 • 2016 ACR/ARHP Annual Meeting
Initial Validation of the Patient Reported Outcomes Measurement Information System Pediatric Pain Intensity Scale in Juvenile Idiopathic Arthritis, Juvenile Fibromyalgia and Sickle Cell Disease
Esi Morgan¹, Constance Mara², Bin Huang³, Adam Carle⁴, Kenneth Goldschneider⁵, Carlton Dampier⁶ and Susmita Kashikar-Zuck⁷, ¹Pediatric Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ²James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Anesthesia, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Department of Pediatrics (Hematology-Oncology), Emory University School of Medicine, Atlanta, GA, ⁷Behavioral Medicine & Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The Patient Reported Outcomes Measurement Information System(PROMIS) is a publicly available assessment system offering multiple measures to assess physical, mental and social health.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].